Cargando…
Correction to: Clinical Potential of Targeting Fibroblast Growth Factor‐23 and αKlotho in the Treatment of Uremic Cardiomyopathy
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660706/ https://www.ncbi.nlm.nih.gov/pubmed/32674722 http://dx.doi.org/10.1161/JAHA.119.014566 |
Ejemplares similares
-
Clinical Potential of Targeting Fibroblast Growth Factor‐23 and αKlotho in the Treatment of Uremic Cardiomyopathy
por: Law, Jonathan P., et al.
Publicado: (2020) -
Role of Fibroblast Growth Factor 23 (FGF23) and αKlotho in Cancer
por: Ewendt, Franz, et al.
Publicado: (2021) -
Correction: Association between Circulating Fibroblast Growth Factor 23, α-Klotho, and the Left Ventricular Ejection Fraction and Left Ventricular Mass in Cardiology Inpatients
Publicado: (2014) -
Correction: Association between Circulating Fibroblast Growth Factor 23, α-Klotho, and the Left Ventricular Ejection Fraction and Left Ventricular Mass in Cardiology Inpatients
por: Shibata, Kensaku, et al.
Publicado: (2013) -
Fibroblast growth factor 23, klotho and heparin
por: Thomas, S. Madison, et al.
Publicado: (2023)